Literature DB >> 7942586

Mechanisms of decreased food intake during weight loss in adult Crohn's disease patients without obvious malabsorption.

D Rigaud1, L A Angel, M Cerf, M J Carduner, J C Melchior, C Sautier, E René, M Apfelbaum, M Mignon.   

Abstract

Because weight loss is common in colonic Crohn's disease and is poorly correlated with disease activity, we analyzed food intake in 63 patients without malabsorption, 30 patients with weight loss (9.2 +/- 4.2 kg), and 33 patients without weight loss. Energy and protein intakes were lower in patients with weight loss than in those with stable weight (P < 0.01). In the former group, food restrictions were more numerous (P < 0.01) and visual analog scales showed less hunger, decreased appetite, and fewer sensations of pleasure related to eating, as compared with the other group (P < 0.01). Food intake reduction was also related to depressive mood and medical advice. However, there was no difference between groups in fecal energy wasting and resting energy expenditure. Weight loss in Crohn's disease may be due to a decrease in food intake rather than to an increase in energy cost of the disease. Thus, focus of attention on the diet is crucial to prevent malnutrition.

Entities:  

Mesh:

Year:  1994        PMID: 7942586     DOI: 10.1093/ajcn/60.5.775

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  24 in total

1.  Enteroendocrine cells: neglected players in gastrointestinal disorders?

Authors:  Gordon W Moran; Fiona C Leslie; Scott E Levison; J Worthington; John T McLaughlin
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 2.  Nutritional status and nutritional therapy in inflammatory bowel diseases.

Authors:  Corina Hartman; Rami Eliakim; Raanan Shamir
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

3.  Immune control of food intake: enteroendocrine cells are regulated by CD4+ T lymphocytes during small intestinal inflammation.

Authors:  J R McDermott; F C Leslie; M D'Amato; D G Thompson; R K Grencis; J T McLaughlin
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

4.  Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone.

Authors:  M Azcue; M Rashid; A Griffiths; P B Pencharz
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

5.  Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner.

Authors:  Matthew Stephens; Pierre-Yves von der Weid
Journal:  Gut Microbes       Date:  2019-06-16

6.  Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.

Authors:  Ryoko Sumi; Kiyokazu Nakajima; Hideki Iijima; Masafumi Wasa; Shinichiro Shinzaki; Riichiro Nezu; Yoshifumi Inoue; Toshinori Ito
Journal:  Surg Today       Date:  2015-10-05       Impact factor: 2.549

Review 7.  Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence.

Authors:  Melissa A Smith; Trevor Smith; Timothy M Trebble
Journal:  Frontline Gastroenterol       Date:  2012-05-21

8.  Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats.

Authors:  M Barbier; C Cherbut; A C Aubé; H M Blottière; J P Galmiche
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

9.  Routine diagnosis of intestinal tuberculosis and Crohn's disease in Southern India.

Authors:  Geir Larsson; Thrivikrama Shenoy; Ramalingom Ramasubramanian; Leena Kondarappassery Balakumaran; Milada Cvancarova Småstuen; Gunnar Aksel Bjune; Bjørn Allan Moum
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  Leptin antagonist ameliorates chronic colitis in IL-10⁻/⁻ mice.

Authors:  Udai P Singh; Narendra P Singh; Hongbing Guan; Brandon Busbee; Robert L Price; Dennis D Taub; Manoj K Mishra; Raja Fayad; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Immunobiology       Date:  2013-05-13       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.